Expression of WT1, CA 125, and GCDFP-15 as Useful Markers in the Differential Diagnosis of Primary Ovarian Carcinomas Versus Metastatic Breast Cancer to the Ovary-Reference-Cited by-同舟云学术

Expression of WT1, CA 125, and GCDFP-15 as Useful Markers in the Differential Diagnosis of Primary Ovarian Carcinomas Versus Metastatic Breast Cancer to the Ovary

Published:2005-11 Issue:11 Volume:29 Page:1482-1489
ISSN:0147-5185
Container-title:The American Journal of Surgical Pathology
language:en
Short-container-title:The American Journal of Surgical Pathology

Author:

Tornos Carmen,Soslow Robert,Chen Shirley,Akram Muzaffar,Hummer Amanda J,Abu-Rustum Nadeen,Norton Larry,Tan Lee K

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pathology and Forensic Medicine,Surgery,Anatomy

Reference29 articles.

1. Metastatic Breast Carcinoma to the Abdomen and Pelvis

2. Pathogenesis of Colloid (Pure Mucinous) Carcinoma of Exocrine Organs

3. Differential expression of MUC2 and MUC5AC mutin genes in primary ovarian and metastatic colonic carcinoma

4. Immunohistochemical Identification of Tumor Markers in Metastatic Adenocarcinoma:A Diagnostic Adjunct in the Determination of Primary Site

5. Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: Metastatic ovarian mucinous carcinoma to the breast: diagnostic challenges and pitfalls;Frontiers in Oncology;2024-03-18

2. Copper nitroprusside: An innovative approach for targeted cancer therapy via ROS modulation;Biomedicine & Pharmacotherapy;2024-02

3. Metastatic Ovarian Serous Adenocarcinoma Clinically Presenting as Inflammatory Breast Cancer;Case Reports in Oncological Medicine;2024-01-10

4. Nontoxic Fluorescent Nanoprobes for Multiplexed Detection and 3D Imaging of Tumor Markers in Breast Cancer;Pharmaceutics;2023-03-15

5. Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission;Cancers;2023-02-25